<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03851952</url>
  </required_header>
  <id_info>
    <org_study_id>PR1117</org_study_id>
    <nct_id>NCT03851952</nct_id>
  </id_info>
  <brief_title>Re-Establishing Flow Via Drug Coated Balloon for the Treatment of Urethral Stricture Disease - Registry Study</brief_title>
  <acronym>ROBUST IV</acronym>
  <official_title>Re-Establishing Flow Via Drug Coated Balloon for the Treatment of Urethral Stricture Disease - Registry Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Urotronic Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Urotronic Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ROBUST IV study is designed to collect and better understand &quot;real-world&quot; outcomes for&#xD;
      men undergoing urethral dilation using the Optilume Drug Coated Balloon (DCB) for treatment&#xD;
      of urethral stricture.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Company Decision&#xD;
  </why_stopped>
  <start_date type="Anticipated">May 31, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stricture Recurrence Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Stricture Free Rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Serious Adverse Events</measure>
    <time_frame>3 months</time_frame>
    <description>Major Device or Procedure Related Serious Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Uroflow</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Change in Qmax (peak flow rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the International Prostate Symptom Score Questionnaire (IPSS)</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>IPSS Percent Responder (50% improvement in IPSS score or IPSS score of 11 or lower)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the EQ-5D Quality of Life Questionnaire</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Change in the EQ-5D at 3 and 12 months post-procedure compared to baseline. Subscales of mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a scale of 1 (no problem) to 5 (extreme problems)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the International Index of Erectile Function Questionnaire (IIEF)</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Change in the IIEF at 3 and 12 months post-procedure compared to baseline on a scale of 5 (severe erectile dysfunction) to 25 (no erectile dysfunction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Male Sexual Health Questionnaire (MSHQ-EjD)</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Change in the MSHQ-EjD at 3 and 12 months post-procedure compared to baseline. Subscales of ejaculatory function from 1 (more ejaculatory dysfunction) to 15 (less ejaculation dysfunction) and bother from 0 (no bother with ejaculation) to 5 (greater bother with ejaculation)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Urethral Stricture</condition>
  <condition>Urethral Stricture, Anterior</condition>
  <condition>Lower Urinary Tract Symptoms</condition>
  <condition>Anterior Urethral Stricture</condition>
  <arm_group>
    <arm_group_label>Optilume DCB</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Optilume Drug Coated Balloon (DCB) treatment for the treatment of urethral stricture as approved for use in Canada</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optilume Drug Coated Balloon</intervention_name>
    <description>The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.</description>
    <arm_group_label>Optilume DCB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male subjects ≥ 18 years old&#xD;
&#xD;
          2. Visual confirmation of stricture via cystoscopy or retrograde urethrogram&#xD;
&#xD;
          3. Single lesion bulbar urethral stricture, less than or equal to 3.0 cm&#xD;
&#xD;
          4. Significant symptoms of stricture such as frequency of urination, dysuria, urgency,&#xD;
             hematuria, slow flow, feeling of incomplete emptying, recurrent urinary tract&#xD;
             infections (UTIs).&#xD;
&#xD;
          5. IPSS score of 13 or higher&#xD;
&#xD;
          6. Lumen diameter &lt;12F by urethrogram&#xD;
&#xD;
          7. Able to complete validated questionnaire independently&#xD;
&#xD;
          8. Qmax &lt;15 ml/sec&#xD;
&#xD;
          9. Guidewire must be able to cross the lesion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Strictures greater than 3.0 cm long&#xD;
&#xD;
          2. Subjects with greater than 1 stricture.&#xD;
&#xD;
          3. Sensitivity to paclitaxel or on medication that may have negative interaction with&#xD;
             paclitaxel&#xD;
&#xD;
          4. Previous urethroplasty within the anterior urethra&#xD;
&#xD;
          5. Stricture due to bacterial urethritis&#xD;
&#xD;
          6. Stricture due to untreated gonorrhea&#xD;
&#xD;
          7. Stricture due to Lichen Sclerosus, or balanitis xerotica obliterans (BXO)&#xD;
&#xD;
          8. Stricture dilated or incised within the last 3 months (apart from subjects on&#xD;
             self-catheterization)&#xD;
&#xD;
          9. Presence of local adverse factors (e.g. abnormal prostate, urethral false passage or&#xD;
             fistula) making catheterization difficult&#xD;
&#xD;
         10. Presence of signs of obstructive voiding symptoms not directly attributable to the&#xD;
             stricture at the discretion of the physician&#xD;
&#xD;
         11. Diagnosis of untreated and unresolved severe BPH or bladder neck contracture (BNC), at&#xD;
             the discretion of the physician&#xD;
&#xD;
         12. Prior diagnosis of overactive bladder (OAB)&#xD;
&#xD;
         13. Diagnosis of severe stress urinary incontinence (SUI), at the discretion of the&#xD;
             physician&#xD;
&#xD;
         14. Previous radical prostatectomy that resulted in either unresolved bladder neck&#xD;
             contracture (BNC) and/or unresolved incontinence&#xD;
&#xD;
         15. Previous pelvic radiation&#xD;
&#xD;
         16. Diagnosis of kidney, bladder, urethral or ureteral stones in the last 6 weeks or&#xD;
             active stone passage in the past 6 weeks&#xD;
&#xD;
         17. Diagnosed with chronic renal failure, at the discretion of the physician&#xD;
&#xD;
         18. A dependence on Botox (onabotulinumtoxinA) in the urinary system&#xD;
&#xD;
         19. Presence of a penile implant, artificial urinary sphincter, or stent(s) in the urethra&#xD;
             or prostate&#xD;
&#xD;
         20. Known neurogenic bladder, sphincter abnormalities, or poor detrusor muscle function&#xD;
&#xD;
         21. Previous hypospadias repair&#xD;
&#xD;
         22. Diagnosis within the last 5 years of carcinoma of the bladder or prostate or suspicion&#xD;
             of prostate cancer (e.g. abnormal DRE or high PSA) at the discretion of the physician&#xD;
&#xD;
         23. Any cognitive or psychiatric condition that interferes with or precludes direct and&#xD;
             accurate communication with the study investigator regarding the study or affect the&#xD;
             ability to complete the study quality of life questionnaires&#xD;
&#xD;
         24. Unwilling to use protected sex for ≥30 days post treatment&#xD;
&#xD;
         25. Unwilling to abstain or use protected sex for 90 days post treatment if sexual partner&#xD;
             is of child bearing potential.&#xD;
&#xD;
         26. Inability to provide legally effective Informed Consent Form (ICF) and/or comply with&#xD;
             all the required follow-up requirements&#xD;
&#xD;
         27. Active infection in the urinary system&#xD;
&#xD;
         28. History of diabetes not controlled with a hemoglobin A1-C &gt;7.0%&#xD;
&#xD;
         29. Diagnosed or suspected primary neurologic conditions such as multiple sclerosis or&#xD;
             Parkinson's disease or other neurological diseases known to affect bladder function,&#xD;
             sphincter function or poor detrusor muscle function.&#xD;
&#xD;
         30. Visible hematuria with subject urine sample without known contributing factor&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron Kodama, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 19, 2019</study_first_submitted>
  <study_first_submitted_qc>February 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2019</study_first_posted>
  <last_update_submitted>July 9, 2019</last_update_submitted>
  <last_update_submitted_qc>July 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urethral Stricture</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

